This is a high-ownership role where you will shape in vivo strategy across multiple programs, establish and grow internal capabilities, and work closely with cross-functional scientific leaders to rapidly advance promising therapeutics from concept to IND.
What You’ll Do
* Own the in vivo strategy across a dynamic portfolio spanning early discovery through IND-enabling studies.
* Partner closely with Biology, Translational, and Program Leadership to ensure strong mechanistic rationale and clinical alignment.
* Drive thoughtful and efficient use of external CROs and academic collaborations to accelerate program progress.
* Contribute directly to PK/PD strategy, dose selection, and translational modeling for small molecules and biologics.
* Support key regulatory packages including IND submissions, data summaries, and briefing documents.
Who You Are
* Ph.D. in Pharmacology, Immunology, Oncology, Cell Biology, or related field with 8+ years of relevant industry experience.
* Deep experience designing and executing in vivo pharmacology studies, ideally in oncology.
* Proven ability to lead in vivo teams and infrastructure, including working under ethical and regulatory frameworks (UK Home Office / FELASA or equivalent is a plus).
* Strong understanding of IND-enabling workflows, including PK/PD and pharmacology packages.
* Clear communicator who thrives in collaborative, fast-moving environments.
* Motivated by impact, scientific rigor, and building something that doesn’t exist yet.